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DNA damage has been long recognized as causal factor for cancer development. When
erroneous DNA repair leads to mutations or chromosomal aberrations affecting onco-
genes and tumor suppressor genes, cells undergo malignant transformation resulting
in cancerous growth. Genetic defects can predispose to cancer: mutations in distinct
DNA repair systems elevate the susceptibility to various cancer types. However, DNA
damage not only comprises a root cause for cancer development but also continues to
provide an important avenue for chemo- and radiotherapy. Since the beginning of cancer
therapy, genotoxic agents that trigger DNA damage checkpoints have been applied to
halt the growth and trigger the apoptotic demise of cancer cells. We provide an overview
about the involvement of DNA repair systems in cancer prevention and the classes of
genotoxins that are commonly used for the treatment of cancer. A better understanding
of the roles and interactions of the highly complex DNA repair machineries will lead to
important improvements in cancer therapy.
Keywords: DNA repair, cancer therapy, aging, genome instability, progeroid syndromes, xeroderma pigmentosum,
ataxia telangiectasia, Fanconi anemia
Introduction
Living organisms have the crucial task to preserve their genome and faithfully transmit it across
generations. Transmission of genetic information is constantly in a selective balance between the
maintenance of genetic stability versus elimination of mutational change and loss of evolutionary
potential. The DNA molecule is under the continuous attack of a multitude of endogenous and
exogenous genotoxic insults and it has been estimated that every cell experiences up to 105 spon-
taneous or induced DNA lesions per day (De Bont and van Larebeke, 2004).
Endogenous damage can result from DNA base lesions like hydrolysis (deamination, depuri-
nation, and depyrimidination) and alkylation (6-O-Methylguanine) or oxidation (8-oxoG) by
intracellular free radical oxygen species (ROS) that can occur as by-products of mitochondrial
respiration (Lindahl and Barnes, 2000). Mutations can also arise during normal cellular metabolism
for instance by erroneous incorporation of deoxyribonucleotides (dNTPs) during replication.
Environmental sources of damage can be physical [e.g., ultraviolet (UV) light, ionizing radiations
(IRs), and thermal disruption] or chemical (e.g., chemotherapeutic drugs, industrial chemicals,
and cigarette smoke) and their effects varies from the formation of cyclobutane pyrimidine dimers
(CPDs) and pyrimidine 6-4 pyrimidone photoproducts (6-4PPs) following UV exposure, to the
introduction of single and double DNA strand breaks upon IR treatment, or to inter- and intrastrand
DNA crosslinks, which result from various chemotherapeutic drugs (Table 1; Ciccia and Elledge,
2010).
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TABLE 1 | Distinct DNA repair systems are specialized to repair the
various types of DNA lesions.
Repair mechanism Lesion feature Genotoxic source
(examples)




Helix-distorting lesions UV radiation
Translesion synthesis Various lesions Various sources
Mismatch repair (MMR) Replication errors Replication
Single stand break repair
(SSBR)
Single strand breaks Ionizing radiation, ROS
Homologous recombination
(HR)
Double-strand breaks Ionizing radiation, ROS
Non-homologous end
joining (NHEJ)




DNA lesions can alter the primary structure of the double
helix thereby affecting transcription and replication. Erroneous
repair of lesions can lead to mutations in the genome that can be
inherited to daughter cells with deleterious consequences for indi-
vidual’s health. As a consequence, eukaryotic cells have evolved a
complex signaling network of repair processes known as the DNA
damage response (DDR). The importance of DNA repair mecha-
nisms is highlighted by the existence of many devastating human
syndromes that are caused by defects in DDR genes. Notably,
many of these mutations generally display increased sensitivity
to DNA damaging agents and predispose to the development of
specific cancer types (Curtin, 2012). Already Theodor Boveri rec-
ognized cancer as a disease of the genome. Indeed mutations and
chromosomal aberrations can lead to alterations in the gene func-
tion. Uncontrolled tumorous cell growth occurs when oncogenes
are activated or tumor suppressor genes inactivated (Figure 1).
The underlying role of DNA damage in cancer development has
become particularly evident when genetic defects in DNA repair
systems lead to increased cancer susceptibility.
DNA Repair Defects Lead to Tumor
Development
Xeroderma Pigmentosum
Xeroderma pigmentosum (XP), Cockayne syndrome (CS), and
trichothiodystrophy (TTD) are rare autosomal recessive diseases
caused by defects in the nucleotide excision repair (NER) pathway
that protects the DNA molecule from the damage inflicted by
UV irradiation (Cleaver, 2005). Indeed, XP was initially described
by the dermatologists Hebra and Kaposi (1874) and was the first
syndrome associated with a defect in a DNA processing pathway
(Cleaver, 1968).
The NER-associated diseases share an increased sun-sensitivity
and freckling in the skin areas exposed to the sun but while XP is a
skin cancer-prone (>1000-fold increase) disease (basal cell cancer,
squamous cell cancer, and malignant melanoma; Kraemer et al.,
1987), CS and TTD are not.
Bypass of unrepaired DNA lesions during replication in divid-
ing cells of XP patients can lead to mutations. Mutations can alter
the sequence and consequently the function of tumor suppressors
and oncogenes. Consequently, XP patients bear not only a highly
elevated risk for developing skin cancer but also a>10- to 20-fold
increase of internal malignancies like leukemias, brain and lungs
tumors before the age of 20 (Bootsma et al., 2001).
XP patients present differences in sunburn reaction that
inversely correlate with cancer risk: 60% of the cases have an
extreme UV light sensitivity directly after birth while the remain-
ing 40% only show visible signs from the age of 2 years where a
freckle-like pigmentation becomesmore evident on the face. Para-
doxically, the latter ones have higher risk to develop cancer. XP
patients can also present, in about 20–30% of cases, neurological
abnormalities (Diderich et al., 2011).
Complementation studies from fibroblasts derived from XP
patients have shed light on the fundamental players involved
in this pathway: mutations in seven different NER genes [from
Xeroderma pigmentosum, complementation group A (XPA) to
Xeroderma pigmentosum, complementation group G (XPG); De
Weerd-Kastelein et al., 1972] plus a variant form, Xeroderma
pigmentosum, complementation group V (XPV), defective in the
translesion DNA polymerase eta (Lehmann et al., 1975), lead
to XP.
Nucleotide excision repair repairs the major lesions caused by
UV light, the CPDs and 6-4PPs that distort the DNA double helix.
A similar type of damage, as well resolved by NER, is caused
by polycyclic aromatic hydrocarbons (tobacco smoke or DNA
crosslinking agents like Cisplatin or Benzopyrene; Leibeling et al.,
2006) and ROS-generated cyclopurines. NER comprises two sub-
pathways: global genome-NER (GG-NER) that scans the entire
genome for helix-distorting lesions and transcription coupled-
NER (TC-NER), which is operating only on actively expressed
genes and is activated when RNA polymerase II stalls at a lesion.
TheNERmechanism consists of fourmain different steps: damage
recognition, DNA unwinding around the lesion, cleavage and
excision of the damaged strand and synthesis of the new DNA
with concomitant final ligation. The only difference between the
two NER branches resides in the DNA damage recognition phase
and for the fact that TC-NER is faster than GG-NER in damage
resolving (Hanawalt and Spivak, 2008).
In the first step of GG-NER, the protein complexes XPC-
HHR23B-Centrin2 and XPE-DDB2 sense the damage and ini-
tiate the repair process by recruiting other NER factors. The
multiprotein complex transcription factor IIH (TFIIH; TFIIH
subunits: XPB, GTF2H1 GTF2H2, GTF2H3, GTF2H4, XPD,
MNAT1, CDK7, CCNH, GTF2H5) generates a transiently open
DNA structure by using the 30-50 and 50-30 nuclease activity of
the two ATP-dependent helicases XPB and XPD (Evans, 1997).
The fundamental role of these proteins is underline by the fact
that XPB and XPD knockout mice are not viable (Cleaver, 2005).
XPD is required not only for its helicase unwinding capacity but
also to verify the damage after XPC loading. The Arch and Fe-S
cluster domains of XPD form a channel where the damaged DNA
is scanned in a 50-30 direction. After unwinding of a 27–30 bp
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FIGURE 1 | DNA damage causes cancer development when
erroneous DNA repair leads to mutations of chromosomal
aberration that activate oncogenes or inactivate tumor
suppressors genes (red). When DNA damage persists and interferes
with replication or transcription, DNA damage checkpoints trigger cellular
senescence or apoptosis that inactivate or eliminate damaged cells and
thus suppress tumorigenesis (gray). DNA repair mechanisms prevent
cancer by preventing mutations. Chemo- and radiotherapy often inflict
DNA damage to halt cancer cell proliferation or trigger the apoptotic
demise of cancer cells.
DNA tract, the exposed filament is completely covered by the
replication protein A (RPA; de Laat et al., 1998). RPA, together
with XPA loading on the 50 side of the lesion (Krasikova et al.,
2010), is involved in the correct positioning of the endonucleolytic
cleavage mediators. The incision step is carried out by two struc-
ture specific endonucleases respectively named XPF-ERCC1 and
XPG. The first cut at the 50-end of the lesion by XPF-ERCC1 is
than followed by the action of XPG on the opposite DNA filament
(Fagbemi et al., 2011). By using the complementary strand as
a template, DNA polymerase  (in non-replicating cells) and "
(in dividing cells) synthesize the new error-free sequence starting
from the 30-hydroxyl extremity generated by XPF-ERCC1. The
remaining 30-end incision is finally closed by Ligase I or III (Moser
et al., 2007).
The TC-NER subpathway initiates when RNA polymerase
stalls at a DNA lesion. XPC, which without XPE is incapable of
binding to CPDs (Fitch et al., 2003; Sugasawa et al., 2005), is
dispensable for TC-NER (Venema et al., 1991). Upon RNAPII
stalling the Cockayne syndrome protein B (CSB) recruits Cock-
ayne syndrome protein A (CSA), whereupon the same NER core
machinery is activated as following GG-NER-mediated damage
recognition. In 80% of the cases CS patients have mutations in
CSB (Natale, 2011) and show neurodegeneration and cachectic
dwarfism. A possible explanation for the lack of tumors observed
in CS patients is the high susceptibility of CS-derived cells to
undergo cell death after DNA damage (McKay et al., 2001). In
addition, it was shown that CS mouse models exhibit reduced
levels of circulating growth factors such as IGF-1 (van der Pluijm
et al., 2007), suggesting that a reduced endocrine growth envi-
ronment might prevent cancer development (Schumacher et al.,
2008).
Ataxia Telangiectasia
The major regulators of the DDR are the two serine-threonine
kinases ATM [ataxia telangiectasia (AT)mutated] andATR (ATM
and RAD3-related) which both belong, together with SMG-1
(suppressor of mutagenesis in genitalia), DNA-PKcs (DNA-
dependent protein kinase catalytic subunit) and mTOR (mam-
malian target of rapamycin), to the phosphonositide 3-kinase
(PI3K)-related protein kinases (PIKKs) family. All of them share a
conservedC-terminal kinase domain structure flanked by the FAT
and FATC domains, two conserved regions, with high sequence
similarity, regulating the kinase activity (Cimprich and Cortez,
2008).
The overlapping substrates of ATM and ATR comprise more
than 700 different proteins mainly involved in DNA repair, cell
cycle arrest, and transcription but also in developmental pro-
cesses, immunity and intracellular protein traffic (Matsuoka et al.,
2007). Among the most important, ATM and ATR respectively
target the two serine-threonine protein kinases: checkpoint kinase
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2 (CHK2) andCHK1, that function as key signal transducers of the
DDR (Bartek and Lukas, 2003). In contrast to ATM and CHK2,
the ATR and CHK1 kinases are indispensable for the viability
of mammalian cells (Brown and Baltimore, 2000; de Klein et al.,
2000).
Humans carrying homozygousmutations (0.5–1%) in theATM
gene (432 mutations have been reported without any hotspots
and generally lead to protein instability—Leiden Open Variation
database) suffer from the neurodegenerative disease AT, which
is characterized by radiation sensitivity, chromosomal instability
and predisposition to cancer. Up to 30% of AT patients develop
lymphoid tumors since ATM play a critical role in the differenti-
ation of T and B cells (Lumsden, 2004). Carriers of heterozygous
missensemutations leading to the expression of inactive but stable
variants acting as dominant ATM version against the wild type
allele have higher incidence to develop breast, colorectal and
stomach cancer (Thompson et al., 2005; Paglia et al., 2009).
Hypomorphic mutations in ATR lead to Seckel syndrome. The
main features of this disease are growth retardation, microcephaly
and a characteristic “bird-headed” facial appearance (O’Driscoll
et al., 2003). While germline ATR mutations have not yet been
reported, ATR was recently found to be downregulated in head
and neck cancers (Moeller et al., 2011) and mutations within
the FAT domain were observed in oropharyngeal-tumor tissue
(Tanaka et al., 2012).
Although they share many substrates, ATM and ATR are acti-
vated in different ways. ATR is mainly induced upon DNA single
strand breaks (SSBs) originated by replication fork stalling or as
result of double strand breaks (DSBs) processing andNER activity.
On the other hand, ATMprimarily responds toDSBs caused by IR
or ROS as well as breaks coming from physiological processes like
meiosis, telomere maintenance, or immune system maturation
(assembly of the T cell receptor and immunoglobulin genes via
V(D)J recombination; Shiloh, 2003).
In the ATR activation process: RPA, after coating the single
strand DNA, recruits the ATR interacting protein (ATRIP). This
complex helps to localize the site of damage (Zou and Elledge,
2003) and to direct the loading of the RAD9-RAD1-HUS1 (9-1-1)
clamp through the interaction with the RAD17-replication factor
C (RFC). After 9-1-1 is loaded on the 50 end of the ssDNA, the
ATR activator topoisomerase-binding protein-1 (TOPBP1) can
be recruited and activates ATR in an ATRIP-dependent manner
(Cimprich and Cortez, 2008). Another mediator of ATR activa-
tion is Claspin (Smits et al., 2010). Activated ATR phosphorylates
CHK1 on Ser317 and Ser345 residues. Additional substrates of
ATR phosphorylation include: ATRIP, Rad17, Rad9, TopBP1,
Claspin, H2AX,WRN, BLM, BRCA1 (breast cancer susceptibility
gene 1), and FANCD2 (Cimprich and Cortez, 2008).
Ataxia telangiectasiamutated is found in the nucleus of undam-
aged cells in the form of inactive dimers or higher order mul-
timers, configuration that inhibit, by masking with the FAT
domain, the kinase domain. UponDNA damage, ATMundergoes
autophosphorylation on residues Ser367, Ser1893, and Ser1981
with the last one located within the FAT domain. These posttrans-
lational modifications result in dimer dissociation and release
of active kinase monomers (Bakkenist and Kastan, 2003; Kozlov
et al., 2006). Upon formation of a DSB, the sensor complex
MRE11-RAD50-NBS1 (MRN), which is composed by the mei-
otic recombination protein 11 (MRE11), the DNA repair protein
RAD50 and the Nijmegen breakage syndrome protein-1 (NBS1),
localize to the damaged area together with ATM (Lee, 2004).
Recently it was reported that ubiquitination of NBS1 by SCF-
Skp2 E3 ligase trigger the recruitment and activation of ATM on
DSB formed upon IR treatment (Wu et al., 2012). Activated ATM
phosphorylates the histone variant H2AX, which is then bound
by the mediator of DNA damage checkpoint protein-1 (MDC1).
MDC1 induces the recruitment of other ATM–MRN complexes
resulting in the establishment of a positive feedback-loop that
leads to further H2AX phosphorylation and amplification of the
initial signal (Lavin et al., 2005). The pool of activatedATMwithin
the cell appear to be divided in two fractions: the first one is
physically bounded toDSB sites while the other one is free to reach
other targets that required to be activated (Shiloh, 2003).
Ataxia telangiectasia mutated exerts its survival function
through the induction of cell cycle checkpoints. In the G1-S
checkpoint, ATM phosphorylates the tumor suppressor p53 on
S15 leading to the disruption of the inhibitory association with
MDM2. Activated p53 induces p21, which binds to and inhibits
the S-phase-promoting Cdk2-CyclinE complex (Sancar et al.,
2004).
During the G2-M checkpoint, ATMphosphorylates monomers
of CHK2 on Thr68 allowing the formation of CHK2 dimers
that have as a main target the cell division cycle 25 homolog A
(CDC25A). Phosphorylated CDC25A can finally be degraded by
the proteasome and prevents cyclin-dependent kinase 2 (CDK2)
and CDK1 dephosphorylation, which is required for progression
through the cell cycle (Cimprich and Cortez, 2008).
Fanconi Anemia
DNA inter- and intrastrand crosslinks represent a dangerous form
of damage blocking vital cellular processes like transcription and
replication. The Fanconi anemia (FA) pathway is responsible to
repair these aberrations arising in the DNA structure as a result of
chemotherapeutics drugs treatment, like cisplatin or mitomycin
C (van der Heijden et al., 2004), or naturally evolved due to the
interaction with lipid peroxidation products such asmalondialde-
hyde (Stone et al., 2008). FA is an autosomal recessive disease
that affects 1 every 100,000 births (Rosenberg et al., 2011) and it
is characterized by growth retardation, infertility, bone marrow
failure and susceptibility to acute myeloid leukemia. Solid tumors
like head and neck, kidney, liver, medulloblastoma, gynecologi-
cal, oesophageal, and skin cancers are also common between FA
patients (Cerbinskaite et al., 2012).
Fanconi Anemia is a heterogeneous genetic disease, 16 different
genes are involved in the establishment of the disorder and they
can be divided in three major groups: the FA core complex,
the I-D2 complex and downstream FA proteins. Eight proteins
form the core complex, respectively named FANCA, FANCB,
FANCC, FANCE, FANCF, FANCG, FANCL, and FANCM while
the I-D2 complex is constituted by FANCD2 and FANCI (Walden
and Deans, 2014). In the initial phase of the process, FANCM,
which forms and heterodimer with FAAP24 (FA-associated pro-
tein 24 kDa), recognizes DNA interstrand cross-links (ICL)
lesions and recruits other FA factors to the damaged site, the
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stalled replication fork. The association of FANCMwith the chro-
matin is strengthened by histone fold protein 1 (MHF1) and 2
(MHF2; Singh et al., 2010) and it is followed by ATR activation
(Schwab et al., 2010). Monoubiquitination of FANCD2 on Lys
561 and FANCI on Lys 523 by the core complex, which essen-
tially constitutes a multisubunit E3 ubiquitin ligase, is the key
step in the activation of the FA pathway (Taniguchi et al., 2002;
Smogorzewska et al., 2007).
Despite the fact that FANCD2 was shown to have intrinsic
nuclease activity (Pace et al., 2010), other nucleases are involved
in the FA pathway and which one is responsible to perform
the first cut and start unhooking the crosslinked DNA is still
unknown. The best candidate to assume this function seems to be
SLX4 (FANCP), which is a multidomain scaffold protein directed
toward branched DNA and Holliday junction (HJ) structures
and able to interact with three distinct nucleases: SLX1, XPF-
ERCC1, and MUS81-EME1. The interaction between SLX4 is
with the NER endonuclease XPF-ERCC1 was indeed shown to
be crucial for the removal of ICLs (Crossan et al., 2011). FAN1
(FA-associated nuclease 1) is another nuclease recruited to the
damaged site by ubiquitinated FANCD2. FAN1 abrogation does
not affect ICLs-induced DSBs formation most likely resembling
the possibility that FAN1 is required further down in the steps of
the repair process (Kratz et al., 2010).
The FA pathway allows resolving the replication fork stalling by
inducing the formation of a DSB and by coordinating the action
of three critical repair mechanisms: translesion synthesis (TLS)
bypasses the lesion and, after toxic adducts removal by NER, the
gap is closed by homologous recombination (HR). The ID com-
plex is finally able to leave the previously damaged area thanks to
deubiquitination mediated by USP1 (ubiquitin specific peptidase
1) and UAF1 (USP1-associated factor 1; Nijman et al., 2005).
Although further work is required to fully understand each
steps of the FA pathway, some of the downstream players involved
are: FANCJ (BRIP1), DNA-dependent ATPase and 50-30 DNA
helicase able to interact with BRCA1; FANCD1 (BRCA2), able to
bind ssDNA and dsDNA and to stimulate RAD51 action; FANCN
(partner and localizer of BRCA2, PALB2), required for FANCD1
stabilization and for the recruitment of BRCA2 and RAD51; and
FANCO (RAD51C) involved in HJ resolution (Kottemann and
Smogorzewska, 2013).
The tumorigenesis of FA is difficult to interpret due to the
overlapping functions of all the aforementioned proteins working
also in homology-directed repair. Of note, the FA pathway is
also active in physiological conditions by preserving the replica-
tion fork stability during S-phase (the I-D2 complex was found
to be ubiquitinated in undamaged cells; Schlacher et al., 2012)
and acts as a barrier against error-prone repair processes such
as non-homologous end joining (NHEJ). Accordingly, genomic
instability, a typical feature of FA patients, was rescued in C.
elegans, DT40 chicken and mammalian cells by inhibiting NHEJ
components (Adamo et al., 2010; Pace et al., 2010).
Breast Cancer Susceptibility Gene 1 and 2
(BRCA1 and 2)
Double strand breaks are the most threatening forms of DNA
damage, if left unrepaired they can lead to chromosomal
rearrangements or to cell death. To counteract DSBs, cells have
evolved two different repair mechanisms: HR and NHEJ. HR is
an error-free way to repair DSBs which takes place during S and
G2 phases of the cell cycle where a sister chromatid is used as a
homologous template (Roy et al., 2011). Vice versa, NHEJ, which
fuses two broken chromosomal ends, can be mutagenic and can
act independently of the cell cycle status (Caestecker and Van de
Walle, 2013).
Two different ways of HR repair coexist: the classic model
and the alternative synthesis-dependent strand-annealing (SDSA)
model. In the first one, also known as Double HJ model, the
50 and 30 ends of a DSB are resected by nucleases (endonucle-
ase Sae2, exonuclease Exo1, helicases Sgs1, and Dna2) and the
30 ssDNA filament invades the intact sister chromatid, which
is used as a template to repair the lesion. The displacement of
the second strand results in the formation of a D-loop. The
extension of the 30 invading strand transforms the D-loop to a
cross-shape structure known as HJ. The second 30 overhang, not
involved in the initial strand invasion, also produces a HJ with
the homologous chromosome. This way of repair may result in
the formation of chromosomal crossovers and principally takes
place during meiosis (Helleday et al., 2007). To avoid the pro-
duction of crossover in somatic cells, event that will end up in
loss of heterozygosity (LOH), the double HJ can be dissolved by
bloom helicase (BML) and Topoisomerase III (Wu and Hickson,
2003).
The SDSA process shares all the steps of the classic HR repair
model except for the absence of the D-loop structure formation
(Sung and Klein, 2006). SDSA always leads to non-crossover
products and is supposed to be the most used way of HR in
mitosis.
Both BRCA1 and BRCA2 are involved in the HR pathway.
BRCA1 and BRCA2 mutations are found in approximately 5–7%
of all hereditary breast cancers (Roy et al., 2011). Inmice, homozy-
gous BRCA1 andBRCA2knockouts die at day 8–9 of development
(Hakem et al., 1996; Suzuki et al., 1997).
Breast cancer susceptibility gene 1 plays major roles in differ-
ent DNA repair mechanisms. It acts in HR, NHEJ and single-
strand annealing (SSA) through its different interaction domains.
Located at the N-terminus, the RING domain is the site for the
interaction with BARD1 (BRCA-associated RING domain 1), a
structurally-related protein responsible for BRCA1 stabilization
and activity (Wu et al., 1996). The BRCA1/BARD1 heterodimer
possesses E3 ubiquitin ligase activity and, upon DNA damage,
mediates downstream signaling events through ubiquitination of
other DDR targets including CtIP, H2AX, RNAPolII, and CstF
(Caestecker and Van de Walle, 2013). At the C-terminus, BRCA1
has a domain shared between many DDR proteins: the BRCT1
domain (BRCA1 C-terminal), required for binding phosphory-
lated proteins during the DDR (Koonin et al., 1996) and essential
for transcriptional regulation and chromatin unfolding (Mon-
teiro, 2000; Ye et al., 2001). In the central part of the protein
we find the DNA binding domain (DBD), the nuclear localiza-
tion and exporting sequences and, most importantly, the serine-
glutamine (SQ) and threonine-glutamine (TQ) motifs which are
indispensable for BRCA1 activation through ATM/ATR phos-
phorylation (Caestecker and Van de Walle, 2013). Most of the
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cancer-associated BRCA1 mutations are found in the RING and
BRCT domains (Roy et al., 2011).
Breast cancer susceptibility gene 1 is a component of three
different multiprotein complexes involved in all cell cycle
checkpoints: the BRCA1A complex (composed of Abraxas,
BARD1, RAP80, BRCC36, BRCC45, and MERIT40), responsible
to recruit BRCA1 to damaged sites; the BRCA1B complex (formed
with BRIP1 and TOPBP1), mainly associated with replication-
coupled DNA repair and the BRCA1C complex (formed together
with CtIP and the MRN complex), which promotes HR despite
NHEJ (Huen et al., 2010).
Interestingly, BRCA1/BARD mutations cannot only fuel
genome instability due to impaired HR activity, but also promote
genome stability as recently shown in C. elegans mutants of the
smc-5/6 complex that leads to replicative impediments and DSB
formation at stalled replication forks (Wolters et al., 2014). The
genome instability in smc-5/6 mutants could be revered upon
inactivation of the BRCA1/BARD complex. It is tempting to
speculate that mutations in BRCA1 might be sustained in the
human genome as under certain conditions of replication fork
breakdown prevention of HR could benefit genome stability.
The BRCA2 protein was recently purified and functionally
validated by three independent research groups (Jensen et al.,
2010; Liu et al., 2010; Thorslund et al., 2010). In contrast to the
multiple functions of BRCA1, BRCA2 main role is to mediate the
recruitment of RAD51 to DSBs during HR. BRCA2 carries, in
the central part of the protein, a DBD able to bind both single
and double stranded DNA and eight BRC repeats indispensable
for the interaction with RAD51. Cancer-associated BRCA2 point
mutations are found between these repeats (Venkitaraman, 2009).
Breast cancer susceptibility gene 2 prevents RAD51 binding to
dsDNA and specifically direct it to ssDNA where it displace RPA
(Thorslund et al., 2010). The PALB2, also known as FANCN, is the
connection between BRCA1 and BRCA2. PALB2 is required for
the colocalization of BRCA1, BRCA2, and RAD51 to the damaged
sites and its dysfunction leads to severe HR defects (Zhang et al.,
2009a).
Mismatch Repair
The critical role of mismatch repair (MMR) in tumorigenesis is
highlighted by the fact that loss of expression of MMR proteins
predispose to colorectal, gastric, endometrial and ovarian cancers
and inherited defects in the MMR genes are associated with the
most prevalent cancer syndrome in humans, the Lynch syndrome
(LS), previously known as hereditary nonpolyposis colorectal
cancer (HNPCC; Guillotin and Martin, 2014). Moreover, MMR
deficiency is present in 15% of all primary cancers (Furgason and
Bahassi el, 2013).
The MMR pathway recognizes base–base mismatches and
insertion-deletion loops (IDLs; Jiricny, 2006) originating from
base misincorporation, tautomeric shifts, slippage of DNA poly-
merases, damage that acts as mismatch, and recombination
duplex. The sequential events in MMR repair comprise damage
recognition, excision, and resynthesis steps (Hsieh and Yamane,
2008). The MutSa and MutSb complexes are the MMR lesion
detectors. The first complex is composed byMSH2 andMSH6 and
recognizes single base-basemismatches and 1–2 bp IDLswhile the
second one, formed by theMSH2 andMSH3 proteins, principally
find and repair 2–12 bp IDLs (Iyama and Wilson, 2013).
Upon DNA binding, one of the three different heterodimeric
complexes MutLa (MLH1-PMS2), MutLb (MLH1-MLH3), and
MutLg (MLH1-PMS1) can be recruited to form, with MutS, a
ternary structure. The complex formed with MutLa is the most
important in the MMR pathway, is able to translocate in both
directions along the damaged area and to recruit proliferating cell
nuclear antigen (PCNA), RFC, and EXO1 to perform the excision
step (Guillotin and Martin, 2014). MutLb function is currently
unknown whereas MutLg is involved in meiotic recombination
(Zhang et al., 2005). After damage resection, resynthesis is carried
out by DNA polymerase  and sealing of the nick by DNA ligase I
(Larrea et al., 2010).
Being part of the replication fork, theMMRmachinery operates
mostly in dividing cells (Wagner andMeselson, 1976), nonetheless
few publications report an active presence of MMR in the brain
(Brooks et al., 1996).
Mismatch repair dysfunction accounts for the mutator phe-
notype in which base substitution and frameshift mutations
are highly increased due to microsatellite instability (MSI).
Microsatellites are short tandem repeated DNA sequences of
1–4 base nucleotides spread all over the genome. Replication of
these repeats has high error risk and when they are present in
tumor suppressor genes, a defective repair may have detrimental
consequences (MSI; Guillotin and Martin, 2014).
DNA Damaging Agents in Tumor Therapy
Cancer therapy was jumpstarted at the end of the Second World
War by serendipity resulting from some of the darkest chapters
of chemical warfare that brought so much suffering during the
First World War. Already in the trenches of the First World War
bone marrow suppression and lymphoid aplasia were reported
upon exposure to the chemicalwarfare sulfurmustard. The critical
link to its therapeutic potential became evident a few decades
later when the secret load of the American vessel S.S. John Harvey
was unleashed in the Italian harbor of Bari during a German air
raid. Physicians detected reduced white blood counts in autopsies
following the incidence. It turned out that the vessel’s load of nitro-
gen mustard had attacked the white blood cells suggesting that
leukemias could be targeted by nitrogenmustard therapy. Already
a few years later the first alkylating agents were introduced to
cancer therapy. Strikingly, it was found that effective chemotaxis
such as nitrogen mustard and cisplatin evoke damage in nuclear
DNA that then results in cell death. Therefore, DNA damage not
only causes tumor development but could also battle cancers by
impairing cancer growth and ultimately triggering the death of
malignant cells (Figure 1).
Cisplatin
Also known as Peyrone’s chloride, cisplatin (cis-
diamminedichloroplatinum) is one of the most widely used
chemotherapeutic drugs. Its antitumor potential was discovered
in the sixties by Rosenberg et al. (1965) when he accidentally
found out that this metal salt was able to inhibit Escherichia
coli cell division. Cisplatin soon drew interest in the scientific
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community and, after its efficacy was proven in mouse models
(Rosenberg et al., 1969), it entered clinical trials and was finally
approved by FDA in 1978 as a chemotherapeutic drug for the
treatment of testicular and bladder cancers (Kelland, 2007b). The
therapeutics properties of cisplatin were then extended to many
other types of cancer including small and non-small cell lung,
head and neck, ovarian, cervical, and colorectal (Lebwohl and
Canetta, 1998; Galanski, 2006).
Once in the cytoplasm, cisplatin gets activated upon reaction
with water, which can substitutes one or both the two cis-chloro
groups of the molecule. The mono aquated form of cisplatin is the
most reactive one, it can reactwithmany cytoplasmic nucleophiles
substrates including reduced glutathione (GSH), methionine and
metallothioneins (MT) but its cytotoxic effect comes from the
capacity to target DNA (Galluzzi et al., 2011). Inside the nucleus,
cisplatin attacks the N7 nucleophilic site of purine bases leading to
the formation of monofunctional adducts. Such adducts are able
to form intra-strand crosslinking structures [90% 1,2 d(GpG) and
10% 1,2 d(ApG)] which represent the major type of DNA damage
exerted by this chemotherapeutic drug (Dasari and Tchounwou,
2014). Cisplatin-mediated damage arrests cells in the G2 phase
of the cell cycle and concomitantly triggers the activation of
DNA repair pathways. If the damage is too severe, programmed
cell death will be induced through the ATM/ATR/TP53 pathway
(Damia et al., 2000; Pabla et al., 2008). Although cisplatin is a
really potent apoptotic inducer, intrinsic or acquired resistance
can represent an obstacle for its use in tumor therapy. Moreover,
cisplatin resistance can either take place before or after DNA
binding.
The copper transporter 1 (CTR1) regulates cisplatin cellular
uptake. Cisplatin treatment of Ctr1 /  mouse embryonic fibrob-
lasts (MEFs) is associated with a reduced intracellular accumu-
lation respect to wild type MEFs (Holzer et al., 2006) and CTR1
downregulation is found in cisplatin-resistant lung cancer cell
lines (Song et al., 2004). Copper pretreatment of cochlear derived
HEI-OC1 cells reduced cisplatin cytotoxicity (More et al., 2010).
In addition to copper transporters, also organic cation trans-
porters (OCTs)were recently discovered to be involved in cisplatin
intake. Even if the uptake is the main cause of altered intra-
cellular cisplatin level, the efflux process must be considered as
well. The ABC ATPases-like multidrug resistance proteins (MRP)
MRP1,MRP2,MRP3,MRP5, and the copperATPasesATP7A and
ATP7B mediate cisplatin export and were found to have altered
expression in cisplatin resistant tumors (Burger et al., 2011).
Cisplatin resistance can also be established through the inter-
action with intracellular thiol-containing molecules such as GSH
andMT. They can both sequester cisplatin within the cytoplasmic
compartment and correlations between their expression level and
cisplatin resistance were found in ovarian, cervical, lung, and
bladder cancer cell lines (Köberle et al., 2010).
Cisplatin-induced DNA damage is primarily repaired by the
FA pathway (Deans and West, 2011), as well as by NER and
MMR. Enhanced activity of these repairmechanisms can promote
cisplatin resistance. Indeed, higher and lower expression levels of
the NER endonucleases ERCC1 and XPF were respectively found
to be associatedwith resistance and sensitivity in ovarian and testis
cancer cell lines (Köberle et al., 1999; Ferry et al., 2000;Welsh et al.,
2004). Moreover, siRNAmediated downregulation of the ERCC1-
XPF complex renders lung, ovarian and breast cancer cells more
prone to death after cisplatin treatment (Arora et al., 2010).
Like NER, also MMR deficiency compromises cisplatin-
induced apoptotic signaling (Topping et al., 2009) and it was
observed to be always associated with an increased translesion
synthesis (TLS) activity (Jung and Lippard, 2007). The specialized
TLS polymerases are therefore another critical target to overcome
resistance in patients carrying MMRmutations.
While cisplatin has a strong anti-cancer activity, it also exerts
negative side effects like nephro- and neurotoxicity (Kelland,
2007a). The negative aspects and the concomitant possibility to
acquire resistance after a certain period of treatment have pushed
researchers, during the last 40 years, to design new platinumbased
drugs.
Approved by FDA in 1989, Carboplatin has, instead of the
two cis-chloro groups, a bidentate dicarboxylate ligand, which
slow down reactivity and unfavorable side effects. Carboplatin is
actually used in the treatment of ovarian, head and neck, and lung
tumors (Dasari and Tchounwou, 2014). The adducts formed by
this molecule are the same ones introduced by cisplatin (Harrap,
1985) and thrombocytopenia is its main negative side effect.
The last platinum drug approved by FDA in 2002 is oxaliplatin.
The large 1,2-diaminocyclohexane ligand plus the oxalate leaving
group confers to oxaliplatin completely new characteristics: it is
less dependent on the CTR1 transporter (Holzer et al., 2006)
and forms DNA adducts which are not recognized by MMR
(Fink et al., 1996). Apart from being effective in the treatment
of cisplatin and carboplatin-resistant tumors (Raymond et al.,
2002), oxaliplatin, in combination with 5-fluorouracil, is success-
fully employed in colorectal cancer treatment (FOLFOX therapy;
Kelland, 2007b).
Between the recently developed platinumbased drugs, phenan-
thriplatin is one of the most promising. This new compound kills
cancer cells more efficiently than cisplatin and oxaliplatin and
appear to be immune to acquired resistance mechanisms (Park
et al., 2012).
Nucleoside Analogs
Nucleoside analogs are anticancer metabolites that were devel-
oped based on modifications of physiological purine (adenosine,
guanosine, inosine) and pyrimidine (cytidine, thymidine, uridine)
nucleosides, the fundamental precursors of ATP, DNA, and RNA.
This class of drugs is widely used in hematological malignancies
and solid tumors and, as well, for the treatment of viral infections
(Galmarini et al., 2002).
Nucleoside analogs exert their cytotoxic activities after being
incorporated into DNA and RNA molecules leading respec-
tively to replication and transcription inhibition, or by directly
interfering with critical enzymes such as polymerases, kinases,
ribonucleotide reductases, methyltransferases, nucleoside phos-
phorylases, and thymidylate synthases (Jordheim et al., 2013). The
cellular uptake of these hydrophilic antimetabolites is mediated
by two major families of nucleoside transporter (NT) proteins:
the equilibrative NTs (ENTs) and the concentrative NTs (CNTs;
Zhang et al., 2007). Within the cell, the same enzymes [deoxy-
cytidine kinase (dCK), deoxyguanosine kinase (dGK), thymidine
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kinase 1 (TK1) and 2 (TK2)] that are responsible for providing
dNTPs for DNA synthesis in resting cells sequentially phospho-
rylate nucleoside analogs to mono, di- and tri-phosphate variants.
Triphosphates represent the active cytotoxic form of nucleoside
analogs (Jordheim and Dumontet, 2007).
Targeting every proliferating cell, the lack of specificity of nucle-
oside analogs leads to negative side effects ranging from bone
marrow suppression with immune system depletion to neurotox-
icity. Concomitantly, targeted cells can also develop resistance
to nucleoside analogs due to decreased activity of the dCK/dGK
activating enzymes or by loss of expression of the NTs.
Cytarabine or ara-c was the first nucleoside analog devel-
oped starting frommodification of 2-deoxycytidine and approved
by FDA in 1969 for acute myeloid leukemia (AML) treatment
(Johnson, 2001). Ara-c carries a hydroxyl group inserted at the
20 position of the sugar and, once inside the cell, becomes phos-
phorylated by dCK. The triphosphate form, ara-CTP, can be
inserted into the DNA in active synthesis instead of deoxycy-
tidine triphosphate (dCTP). Since the 30–50 proofreading activ-
ity of DNA polymerases is slower than ara-CTP incorporation,
the modified newly inserted nucleoside, which is not a good
30 substrate for DNA polymerases, will lead to the stalling of
the replication fork (Ross et al., 1990). Gemcitabine is also a
2-deoxycytidine analog with two fluorine introduced in the 20
position of the sugar. Like cytarabine, the antitumor activity of
this molecule is due to the incorporation of the triphosphate
form into DNA and concomitant competition with dCTP (Hertel
et al., 1990). Gemcitabine has the capacity to inhibit ribonu-
cleotide reductase and therefore decreasing the deoxynucleotide
pools (Wang et al., 2007). This nucleoside analog is active in
solid tumors such as pancreatic, breast, ovarian and non-small
cell lung cancers (Ewald et al., 2008). Gemcitabine was shown to
have a better cellular uptake, a longer retention time (Plunkett
et al., 1995) and to enhance the antiproliferative capacities of
cisplatin in combination regimen treatment (van Moorsel et al.,
2000).
While the stereochemical form of natural nucleosides is the b-
-configuration, Troxacitabine is a different kind of pyrimidine
analog forming the opposite conformation, the b-l. Its uptake
is not mediated by ENTs or CNTs and it is phosphorylated by
a different type of kinase, the 3-phosphoglycerate kinase. Trox-
acitabine’s antiproliferative activity was demonstrated in clinical
trials for both solid and hematological malignancies (Swords
and Giles, 2007). CNDAC is a cytosine analog with a com-
pletely different way of action. In contrast to ara-c, gemcitabine
and troxacitabine-mediated cytotoxicity that is achieved through
replication fork stalling with concomitant S-phase arrest, CNDAC
antiproliferative effects are derived from the capacity to induce
G2 arrest and to induce DNA DSBs (Wang et al., 2008). Fludara-
bine and Cladribine, which are used for the treatment of blood
malignancies, represent examples of purine analogs based on
modifications of 20-deoxyadenosine. Fludarabine has a fluorine
atom at the 20 position of adenosine plus a phosphate group at
the 50 carbon of the arabinose ring while the only modification of
cladribine is, instead of the fluorine, a chlorine atom in the 20 site
of the sugar. Like their pyrimidine analogs, also these molecules
are internalized by theNTs, they undergo the same activation steps
and they ultimately kill cells by activating the DDR upon DNA
incorporation (Huang et al., 1990). Fludarabine and Cladribine
were reported to also interfere with the activity of ribonucleotide
reductase, DNA ligase, DNA primase (Clarke et al., 2001) and to
induce apoptosis through APAF-1 (Genini et al., 2000). Of note,
both drugs result cytotoxic also for non-dividing cells (Galmarini
et al., 2002).
Clofarabine is another purine analog that was developed in
order to ameliorate the two aforementioned predecessors and it
was brought into use in 2006 for the treatment of pediatric acute
lymphoblastic leukemia (ALL; Bonate et al., 2006). It carries a
fluorine atom at the 20 site of the purine which increases the
stability of themolecule and, like gemcitabine and fludarabine, the
triphosphate form of clofarabine blocks DNA synthesis, inhibits
ribonucleotide reductase and triggers apoptosis by directly affect-
ing the release of cytochrome c from the mitochondria (Ewald
et al., 2008). In addition, clofarabine showed in vitro cytotoxicity
also in non-small cell lung, colon, central nervous system, ovarian,
renal, prostate, and breast cancer cell lines (Bonate et al., 2006).
Alkylating Agents
Alkylating agents are one of the oldest antineoplastic drugs. The
first glimpse of a therapeutic potential of this class of compounds
appeared during the first world war when it was noticed that peo-
ple exposed to sulfur mustard, a chemical warfare, were develop-
ing bone marrow suppression and lymphoid aplasia (Krumbhaar
and Krumbhaar, 1919). In 1949, Chlormethine, sold under the
name of Mustargen, was the first alkylating agent to be approved
by FDA for the treatment of leukemia and lymphomas. Alkylating
drugs function during all phases of the cell cycle via formation
of reactive intermediates, which attack nucleophilic groups on
DNA bases with high negative potential. Of consequence, the
primary targets of alkylating agents are purines with N7- and O6-
methyl guanine being themost stable in vitromethylation adducts
(Kondo et al., 2010). Base alkylation can also occurs on adenines
on positions N1, N3, N6, N7. Pyrimidines can as well be alkylated:
cytosines on positions N3 and O2 and thymidines on O2, N3, and
O4 sites (Puyo et al., 2014). Alkylation of oxygen atoms can be
highly mutagenic, while N-akylations are more cytotoxic. RNA,
proteins, and lipids can also be targets of alkylation. Alkylating
agents can be either mono- or bifunctional depending on the
number of active sites they have and the possibility to react with
one or twoDNA strands.Monoalkylating agents transfer one alkyl
group to their targets resulting in a single basemodification and, if
not promptly repaired, lead to relative base mispairing (alkylated
guanines can wrongly pair with thymines) or to strand breakage
due to the formation of an apurinic/apyrimidinic (AP) site. On
the other side, the two electrophilic sites of bifunctional agents
can attack two different bases on the same or on opposite DNA
filaments to form intra- or interstrand crosslinks, respectively,
which potentially inhibit strand separation during replication or
transcription.
DNA crosslinks can also be introduced as a result of the
interaction between two adjacent bases previously modified by
monofunctional agents (Fu et al., 2012). Alkylating agents used in
chemotherapy are divided in six groups: nitrogen mustards, alkyl
sulfonates, ethylenimines, triazines, and nitrosoureas.
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Nitrogen mustards represent the oldest group of bifunctional
alkylating agents initially used to treat cancer patients. Due to the
short half-life and high toxicity, the use of chloremethine, the pro-
genitor of this class of compounds, is actually restricted to veteri-
nary medicine but many of its derivatives were developed and are
actually applied in the treatment of different neoplasias. Chloram-
bucil and Bendamustine are used for treating chronic lymphocytic
leukemia (CLL). Melphalan, apart from being implied in breast
and ovarian cancers, Hodgkin’s disease and neuroblastoma, is the
standard treatment, in combination with prednisone, for multiple
myeloma (Alexanian et al., 1967).
Cyclophosphamide, the most used drug of this class of agents,
possesses the broadest spectrum of anticancer activity. In addition
to its beneficial role in hematological malignancies, it is also effec-
tive in the treatment of solid tumors like bladder, brain, breast,
cervix, endometrium, lung, ovary, and testis (Emadi et al., 2009).
Ifosfamide is structurally similar to cyclophosphamide and it is as
well utilized in solid tumors such as cervix, testes, head and neck,
breast, ovary, and lung tumors. Cyclophosphamide and ifosfamide
are prodrugs that require activation in the liver by cytochromes
p450.
Busulfan belongs to the class of alkyl sulfonates and is one of
the most important bifunctional agent for the cure of chronic
myelogenous leukemia (CML; Haut et al., 1961), lymphomas and
myeloproliferative disorders.
Thiotepa and altretamine are examples of another class of
bifunctional alkylating agents, ethyleneimines. The first one is
used for ovarian, breast, and bladder cancer (van Maanen et al.,
2000), while the second one has shown positive effects for recur-
rent ovarian cancer following cisplatin therapy (Chan et al., 2003).
Triazines and nitrosoureas represent two classes of mono-
functional alkylating agents with the main difference in their
donor alkyl group: a methyl for triazines and chloroethyl for
nitrosoureas. Examples of triazines are dacarbazine, an hepatic
activable agent included in the treatment of melanoma (Hersh
et al., 2011) and temozolomide which is used for primary brain
tumors thanks to its high bioavailability in the nervous system
(Stupp et al., 2005). Nitrosoureas reduce the in vitro prolifer-
ation of different cancer cell lines (Gnewuch and Sosnovsky,
1997) and possess activity against solid and non-solid tumors.
Carmustine, lomustine, nimustine, and fotemustine are examples
of nitrosoureas derivatives that need to be considered for the
treatment of brain tumors and skin cancer.
The classic negative side effects of alkylating agents are nausea
and fatigue as well as myelo- and immunosuppression and cardiac
dysfunction. In addition, most of these chemotherapy agents have
mutagenic and carcinogenic potential.
The products of mono N-alkylation are repaired by base exci-
sion repair (BER) or direct reversal. BER is initiated by DNA
glycosylases, which recognize and remove theDNA lesionwith the
concomitant formation of an abasic (AP) site. The AP site is then
processed by specific endonucleases and the missing nucleotide
is inserted by DNA polymerase-b. Sealing of the nick is per-
formed by DNA ligase, which finally restores the DNA integrity
(Kim and Wilson, 2011). The BER pathway specifically repairs
N7MeG, N3MeA, and N3MeG and downregulation of BER com-
ponents [APE1 endonuclease, polymerase-b, poly (ADP-ribose)
polymerase (PARP)] was shown to sensitize tumors to alkylating
agents (Liu and Gerson, 2004).
The human AlkB homologs ABH2 and ABH3 are demethy-
lases that catalyze the direct reversal of the following lesions:
N1MeA, N3MeC, N3MeT, and N1MeG (Aas et al., 2003). Like
for BER deficiency, inhibition of AlkB proteins enhances the
chemotherapeutic effects of alkylating drugs (Ralhan and Kaur,
2007). Alkylations of the oxygen atoms, on the other hand, are tar-
gets of the repair protein methylguanine DNA methyltransferase
(MGMT), which is able to transfer the inserted alkyl groups into
its own active site in an auto-inactivating reaction (Pegg et al.,
1994). MGMT importance is underlined by the notion thatmgmt
deficient cells are more sensitive than wild type to methylating
agents (Day et al., 1980) while MGMT overexpression correlates
with resistance to temozolomide (Kaina et al., 2007). MGMT is
an optimal candidate to be taken in consideration to sensitize
alkylating agent-resistant cancers. In this regard, inhibitors like
O6-benzyl guanine (O6-BG), a pseudosubstrate of MGMT, have
been proved to enhance the response to temozolomide in cells
with high level of MGMT (Zhang et al., 2009b).
O-alkylations can also be repaired byNER orMMR. In contrast
to MGMT, MMR presence is indispensable for the antiprolif-
erative activity of alkylating agents: in MMR deficient cells, the
damage accumulates but is not translated in the apoptotic signal.
Abrogation of MMR rescues the sensitivity of mgmt  /  mice to
N-methyl-N-Nitrosourea (Klapacz et al., 2009).
All the aforementioned repair systems act together with HR,
FA, and TLS pathways to solve the more complex lesions caused
by the action of bifunctional alkylating agents. The interstrand
DNA crosslinks introduced by the latter are usually repaired
previous transformation in DSBs (Kondo et al., 2010). Target-
ing key proteins involved in these processes could represent an
attractive strategy to enhance the tumor response to this class of
chemotherapeutic drugs.
PARP1 Inhibitors
Personalized medicine uses targeted therapies on specific patients
cohorts and PARP1 inhibitors represent a new promising class
of chemotherapeutic drugs adopted to exclusively disrupt PARP1
function in HR-defective cancers.
PARP1 belongs to a family of 17ADP-ribosyltransferases which
utilize nicotinamide adenine dinucleotide (NAD+) molecules as
a substrate to form polymers of ADP ribose units (PAR) on
target proteins. This post-translational modification, known as
PARylation (Chambon et al., 1964), is a reversible fundamental
process of the DDR necessary for recruiting to the damaged site
PAR-binding factors involved in chromatin architecture andDNA
repair. PARP1 is the most expressed member of the family, it
has nuclear localization and it plays a major role in BER by
associating with SSBs and recruiting crucial repair proteins like
X-ray repair cross-complementing protein 1 (XRCC1; Rouleau
et al., 2010). In addition, PARP1 is part of the HR and NHEJ
machineries thanks to the interactions respectively with MRE11,
RPA, RAD51 (Bryant et al., 2009), and ligase IV (Li et al.,
2013).
Synthetic lethality is the phenomenon by which combina-
tions of mutations in two or more genes is lethal whereas single
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mutation of only one is compatible with viability (Reinhardt et al.,
2009).
PARP1 inhibition was found to be effective in the treatment
of tumors carrying mutations in BRCA1 or BRCA2 genes. In
these tumors, the accumulation of SSBs, upon treatment with
PARP1 inhibitors, leads to stalling of replication forks and to the
formation of DSBs, which cannot be repaired in the absence of
functional BRCA1 and/or BRCA2 proteins finally resulting in
high level of genomic instability and eventually cell death. Thus,
by exploiting the concept of synthetic lethality, PARP1 inhibitors
selectively kill malignant cells that areHRdeficient (Rouleau et al.,
2010). Since PARP1 dissociation from DNA is mediated by auto-
PARylation, PARP1 inhibitors exert their cytotoxic effects also by
causing a permanent bound of PARP1 to SSBs thereby inhibiting
the accessibility of other PARP proteins to the DNA lesion (Elvers
et al., 2011).
Besides BRCA1 and BRCA2, sensitivity to PARP1 inhibitors
was also observed in vitro for the deficiency of other HR genes
including RAD51, RAD54, DSS1, RPA1, NBS1, ATR, ATM,
CHK1, CHK2, FANCD2, FANCA, and FANCC (McCabe et al.,
2006). This finding support the notion that BRCA associated
cancers respond to PARP1 inhibitors due to abnormal HR and
indicate this therapy as a possible treatment for all of the tumors
displaying features of “BRCAness.” Olaparib was the first PARP1
inhibitor to be approved by the US FDA for the treatment of
ovarian cancers with BRCA mutations but many others (e.g.,
Iniparib, Rucaparib, Niraparib, Veliparib, and BMN-673) are cur-
rently assessed in clinical trials, alone or in combination with
either chemo or radiotherapy, for several “non-BRCA” tumors
(Tangutoori et al., 2015).
Radiotherapy
Together with surgery and chemotherapy, radiotherapy represents
a common treatment option for 50% of cancer patients (Delaney
et al., 2005). By releasing large amounts of energy that can be
adsorbed by atoms or molecules, IR can directly damage the
chemical structure of genetic material and it is consequently used
to block cancer cells proliferation and inducing cell death (Jackson
and Bartek, 2009). Radiotherapy is given alone or in combina-
tionwith chemotherapy (chemoradiotherapy) or before (neoadju-
vant treatment), during (concurrent treatment) and after surgery
(adjuvant treatment) and it can be delivered onpatients eitherwith
external devices or, internally, with sealed radioactive sources
placed inside the body near the tumor area (brachytherapy; Baskar
et al., 2012). Unsealed radiation sources (such as iodine, phospho-
rus, strontium, or samarium), sometimes bound to an antibody
directed to themalignant cells, represent the lastmethod to deliver
IR in tumor therapy. This class of radiopharmaceuticals drugs are
present in liquid forms and usually administered orally or by vein
injection (Wallner, 2006).
Apart from being used for curing, radiotherapy can also be
adopted with palliative intent to release the pain associated with
specific types of cancer.
Photons (X-rays and gamma rays) and charged particles are the
main forms of IR utilized in cancer therapy. X- and gamma rays
represent widely used photon beams with low radiation charge
generated respectively from electrons exciting devices and from
the decay of radioactive substances like caesium, cobalt or radium.
Once they enter the body, electromagnetic waves of photons do
not stop on their targets but they keep going and affecting the
surrounding healthy tissues by interacting with the electrons of
other molecules. Moreover, the radiation dose decreases as the
depth of penetration in the body increase (Hall andGiaccia, 2011).
In photon therapy, most of the DNA damage is inflicted indi-
rectly by the reaction with free radicals species formed upon
ionization of water components. Of consequence, the availability
of oxygen becomes one of the major limitations in treating solid
tumors that are known to be hypoxic. To overcome this problem,
chemical radiosensitizer that can react with free radicals in a sim-
ilar way to oxygen have been developed. Nimorazole and Sanazole
represent the best examples of oxygen mimicking drugs actually
adopted in the clinic (Lomax et al., 2013).
Charged particles radiation therapy use cyclotron and syn-
chrotron to accelerate electrons, protons or heavy ions like carbon
causing direct DNA damage due to the higher linear energy
transfer (LET) capacity. The large mass of protons and other
charged particles, and their unique absorption profile (Bragg’s
peak:maximum release of energywhen the particles stop traveling
through the body) minimize the lateral side scatter and inflict a
more precise damage to the target (Allen et al., 2011). Although
radiotherapy is one of the most effective ways to kill a cancer
cell, it causes both early (acute) and late (chronic) side effects due
to killing of normal cells and triggering inflammatory responses.
Fatigue and sore skin are the most common acute side effects
while the chronic ones largely depends on which part of the
body is treated with the possibility to develop secondary cancers.
Technological advances, like the use of image-guided (IGRT)
or intensity-modulated radiotherapy (IMRT), have made a great
progress in precisely delivering IR to patients without affecting
healthy tissues but the effectiveness of the treatment does not rely
only on this aspect. Other factors, such as the genetic background
of the patient, have to be considered to maximize the benefit of
radiotherapy (Thoms andBristow, 2010). Asmentioned before, IR
attacks directly or indirectly the DNA molecule inflicting lesions
that range from abasic site to the more cytotoxic SSBs and DSBs
(Wallace, 2002). DNA damage sensing and repair mechanisms,
and their status within a specific tumor subtype, are therefore of
great importance in the establishment of cancer cell sensitivity
to radiotherapy and for assessing how their modulation can be
exploited in chemoradiotherapy. Inhibition of cell cycle check-
pointsmediated by CHK1 andCHK2 or proteins involved in BER,
such as APE or POLQ, or in DSBs repair, like ATM or DNA-PK,
have indeed been shown to sensitize cancer cells to radiotherapy
(Begg et al., 2011).
Concluding Remarks
DNA damage occurs on a daily basis by endogenous and exoge-
nous sources. Distinct DNA repair systems recognize and remove
the lesions. When the damage remains unrepaired DNA damage
checkpoints can halt the cell cycle or induce cellular senescence
or apoptosis. Erroneous repair or replicative bypass of lesions
can result in mutations and chromosomal aberrations. When
mutations affect tumor suppressor genes or oncogenes, cell might
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transform into cancer cells. Therefore, DNA repair is essen-
tial for preventing tumor development. However, once a can-
cer has developed, DNA damage can be exploited to reduce
cancerous growth and evoke apoptotic demise of cancer cells.
Thus, chemo- and radiotherapies are still today, over 60 years
after having been first introduced into tumor therapy, impor-
tant strategies to fight cancer. Given the central role of genome
instability in triggering and treating cancer, it is likely that
genotoxic treatments will remain an important avenue of can-
cer therapy. Also the better understanding of DNA repair sys-
tems will allow therapies that specifically target selected repair
pathways. It will be of particular importance to gain a deeper
understanding how the various DNA repair systems interact
with each other in the context of cellular homeostasis and DNA
metabolism in order to optimize targeted approaches to cancer
therapy.
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